2026-05-11T09:00:52-05:00 2025-12-31 050409384 KAHN LITWIN RENZA & CO LTD 951 NORTH MAIN STREET PROVIDENCE RI 02904 990 2025-01-01 522396428 ALZHEIMER'S DISEASE RESEARCH FOUNDATION ALZH 7812373800 34 WASHINGTON ST 230 WELLESLEY HILLS MA 02481 MARGARET E SMITH CEO & DIRECTOR 7812373800 2026-05-11 1 SANDY ROSS P01399337 4012742001 2026-05-08 2025 2025-03-06 01:10:19Z CURE ALZHEIMER'S FUND MARGARET E SMITH 34 WASHINGTON ST 230 WELLESLEY HILLS MA 02481 62464569 0 X HTTP://CUREALZ.ORG/ X 2004 PA TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. 11 10 38 100 0 0 30788755 55333840 0 0 964653 1312647 2269 13348 31755677 56659835 28828950 37323497 0 0 5244116 5904594 0 0 2357449 2926002 3004585 36999068 46232676 -5243391 10427159 28586231 43169584 1722043 6057359 26864188 37112225 X TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. ALL OVERHEAD EXPENSES ARE PAID BY THE BOARD OF DIRECTORS, TRUSTEES AND CORE GROUP OF OTHER DONORS, ALLOWING 100% OF GENERAL DONATIONS TO FUND OUR RESEARCH PROGRAMS. 0 0 38338893 37323497 IN 2025, CURE ALZHEIMER'S FUND SUPPORTED 161 RESEARCH PROJECTS AT 74 LEADING RESEARCH INSTITUTIONS, FOR A TOTAL RESEARCH OUTPUT OF $38.3 MILLION. PROJECTS IDENTIFIED AND INVESTIGATED MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE AS POTENTIAL THERAPEUTIC TARGETS. OTHER STANDALONE PROJECTS AND MULTI-LAB CONSORTIA PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF NEUROINFLAMMATION, THE GUT MICROBIOME, AND THE IMMUNE SYSTEM IN HEALTHY BRAIN FUNCTION. CUREALZ ALSO PROVIDED FUNDING TO SUSTAIN VITAL RESEARCH ASSETS, LIKE BRAIN BANKS AND SCIENTIFIC TRAINEES, FACING UNANTICIPATED REDUCTIONS IN FEDERAL SUPPORT. ADDITIONAL EXPENSES INCLUDE SCIENTIFIC MEETING HOSTING; HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES. 4220285 CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, WEBINARS, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED FOR MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. 42559178 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 41 0 38 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 11 10 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA X X X MARGARET E SMITH 7812373800 34 WASHINGTON STREET STE 230 WELLESLEY HILLS MA 02481 MARGARET E SMITH CEO & DIRECTOR 40.00 X X 501560 0 29619 HENRY MCCANCE CHAIR & DIRECTOR 5.00 X X 0 0 0 PHYLLIS RAPPAPORT TREASURER & DIRECTOR 5.00 X X 0 0 0 TIMOTHY ARMOUR DIRECTOR 3.00 X 0 0 0 RICHARD BIRNBAUM DIRECTOR 4.00 X 0 0 0 BRITTANY BOWLEN DIRECTOR (AS OF 5/25) 3.00 X 0 0 0 MARK FAGGIANO DIRECTOR 3.00 X 0 0 0 MARY GREENHILL CAGLIERO DIRECTOR 3.00 X 0 0 0 KUMAR MAHADEVA DIRECTOR 3.00 X 0 0 0 JACQUELINE MORBY DIRECTOR 4.00 X 0 0 0 CHRISTINE VILLAS-BOAS DIRECTOR (AS OF 3/25) 3.00 X 0 0 0 JOSEPHINE ANTONELLIS CFO 30.00 X 225192 0 8002 LAUREL LYLE SECRETARY & VP, BOARD RELATIONS & DEV. 30.00 X 133686 0 4655 KATHARINE HERMAN EVP DEVELOPMENT 40.00 X 458522 0 31035 BARBARA CHAMBERS EVP MARKETING & COMM. 40.00 X 303031 0 24478 DANIEL HARPER VP DEVELOPMENT 40.00 X 220918 0 14361 LISA RAND VP MARKETING & COMM. 40.00 X 217091 0 19494 JOHN SLATTERY SVP, PHILANTHROPIC PARTNERSHIPS 40.00 X 213548 0 7462 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 40.00 X 193723 0 26754 THIDAPHORN SENGSAVANH DIRECTOR OF DEVELOPMENT OPERATIONS 40.00 X 170896 0 25682 2638167 0 191542 19 0 1 0 PROPER VILLAINS LLC 855 BOYLSTON STREET 10TH FLOOR BOSTON MA 02116 CREATIVE AND PRODUCTION SERVICES 130663 1 321940 55011900 5675241 55333840 1334483 1334483 5687546 5709382 -21836 -21836 -21836 108700 321940 95352 13348 13348 56659835 0 0 1325995 33812354 33812354 3511143 3511143 1719780 929771 412287 377722 3414234 1994996 454082 965156 80940 50437 8766 21737 336158 193636 55697 86825 353482 199198 60093 94191 105987 963 18560 86464 40676 40676 53906 53906 597442 322780 48011 226651 811566 811566 180267 108285 26885 45097 176806 77747 72554 26505 96980 56117 15933 24930 133968 56599 1110 76259 349673 299741 18702 31230 2896 744 476 1676 28809 5267 21202 2340 GIFT PROCESSING FEES 266060 266060 RESEARCH LAB EXPENSES 86974 86974 MISCELLANEOUS 72575 40860 7109 24606 46232676 42559178 1316049 2357449 2815537 3565286 322954 1802130 1707733 9622053 246040 321471 8688 3620 7964 5068 23255145 27704096 230858 149480 28586231 43169584 167083 363629 600901 4812010 954059 881720 1722043 6057359 X 25165313 26004933 1698875 11107292 26864188 37112225 28586231 43169584 10427159 -179122 0 X X 0 1 X 1 0 X 26547838 32354655 36697205 30788755 55362142 181750595 26547838 32354655 36697205 30788755 55362142 181750595 14368215 167382380 4497 93408 992260 997714 1334483 3422362 185172957 397698 0.90390 0.86450 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8688 3620 5068 5068 ACCRUED PAYROLL AND RELATED 739590 LEASE PAYABLE 142130 881720 X 56426807 -179122 -179122 56605929 53906 53906 56659835 46178770 0 46178770 53906 53906 46232676 PART X, LINE 2: THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE ORGANIZATION ANNUALLY FILES IRS FORM 990 RETURNS OF ORGANIZATIONS EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) - BELGIUM, FINLAND, GERMANY, NETHERL 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 2488952 MIDDLE EAST AND NORTH AFRICA - ISRAEL 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 7763 EAST ASIA AND THE PACIFIC - AUSTRALIA, SINGAPORE 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 402388 NORTH AMERICA - CANADA 0 0 GRANTS AWARDED ALZHEIMER'S DISEASE RESEARCH 612041 0 0 0 0 0 0 3511144 0 3511144 AUSTRALIA DEVELOPING BRAIN-TARGETED AAVS USING HUMAN BLOOD-BRAIN BARRIER RECEPTORS 201138 WIRE TRANSFER 0 BELGIUM BRAIN-PENETRANT COMPLEMENT BLOCKING VHHS TO REDUCE NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE 166750 WIRE TRANSFER 0 BELGIUM PRECLINICAL ANALYSIS OF SYNAPTOGYRIN-3 OLIGONUCLEOTIDES TO TARGET TAUOPATHY 201250 WIRE TRANSFER 0 BELGIUM BAC: THE 100-PLUS STUDY BRAIN COHORT: IDENTIFYING MOLECULAR DETERMINANTS OF RESISTANCE, RESILIENCE AND EARLY COGNITIVE DECLINE IN THE OLDEST-OLD 287500 WIRE TRANSFER 0 CANADA UNRAVELLING PRECISION HORMONE THERAPY USING MENOPAUSE AND HORMONE THERAPY TYPE ACROSS APOE GENOTYPE 201250 WIRE TRANSFER 0 CANADA ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER 7763 WIRE TRANSFER 0 CANADA ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER 47115 WIRE TRANSFER 0 CANADA REFERENCE INTERVALS FOR PLASMA P-TAU-217 IN THE CANADIAN POPULATION 57500 WIRE TRANSFER 0 CANADA APOE CONSORTIUM: APOE AND IMMUNE CHECKPOINT REGULATION DURING AGING 298414 WIRE TRANSFER 0 FINLAND NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE 23000 WIRE TRANSFER 0 GERMANY CHARACTERIZATION OF THE LONGITUDINAL TRAJECTORIES OF THE SYNAPTIC BLOOD MARKER -SYNUCLEIN DURING AD PATHOGENESIS AND IMPROVEMENT OF THE MEASUREMENT PROCEDURE 111780 WIRE TRANSFER 0 GERMANY CHARACTERIZATION OF THE LONGITUDINAL TRAJECTORIES OF THE SYNAPTIC BLOOD MARKER -SYNUCLEIN DURING AD PATHOGENESIS AND IMPROVEMENT OF THE MEASUREMENT PROCEDURE 34500 WIRE TRANSFER 0 ISRAEL ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER 7763 WIRE TRANSFER 0 NETHERLANDS UNDERSTANDING THE DYNAMIC LIPID-IMMUNOMETABOLOME OF PROTECTIVE AND RISK ALZHEIMER MICROGLIA 201250 WIRE TRANSFER 0 NORWAY ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE 108000 WIRE TRANSFER 0 SINGAPORE MULTIDIMENSIONAL PROFILING OF TREM2-MUTATED OR APOE4-MUTATED MICROGLIA IN HUMAN BRAIN ORGANOIDS TO UNDERSTAND DYSREGULATED MICROGLIA NEURONAL CROSSTALK IN AD 201250 WIRE TRANSFER 0 SWEDEN ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE 90620 WIRE TRANSFER 0 SWEDEN CHARACTERIZATION OF TAU PATHOLOGY HETEROGENEITY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM 201250 WIRE TRANSFER 0 SWEDEN UNDERSTANDING AMYLOID PATHOLOGY - MULTIOMIC ACTIVITY IMAGING OF PLAQUE FORMATION DYNAMICS (AMYMAP) 84004 WIRE TRANSFER 0 UNITED KINGDOM BRAIN-PENETRANT COMPLEMENT BLOCKING VHHS TO REDUCE NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE 33638 WIRE TRANSFER 0 UNITED KINGDOM SCALING THE DIVIDE IN ALZHEIMER'S DISEASE: AN INTEGRATED MOLECULAR, CELLULAR AND NETWORK-LEVEL STUDY 201199 WIRE TRANSFER 0 UNITED KINGDOM USING LONG-READ SEQUENCING TO INVESTIGATE THE MAPT LOCUS AND TRANSCRIPTS IN NEURODEGENERATION 201250 WIRE TRANSFER 0 UNITED KINGDOM CELLULAR VULNERABILITY TO PATHOLOGICAL TAU PROTEIN ACCUMULATION IN ALZHEIMER'S DISEASE 229770 WIRE TRANSFER 0 UNITED KINGDOM INVESTIGATING THE SERIAL PATHOLOGIES RELATED TO PLASMA BIOMARKERS IN NLFTAUM/H MICE; A NEW MOUSE MODEL FEATURING NEUROFIBRILLARY TANGLES AS A RESULT OF RISING AMYLOID WITHOUT MAPT MUTATIONS 197083 WIRE TRANSFER 0 UNITED KINGDOM UNDERSTANDING AMYLOID PATHOLOGY - MULTIOMIC ACTIVITY IMAGING OF PLAQUE FORMATION DYNAMICS (AMYMAP) 116107 WIRE TRANSFER 0 19 0 0 0 0 0 0 0 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. FISHER ISLAND GOLF 430640 321940 108700 62400 7664 25288 430640 321940 108700 62400 7664 25288 95352 13348 1 AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC 1120 15TH STREET CJ3301 AUGUSTA GA 30912 581418202 501 (C)(3) 201250 0 THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA HOUSTON TX 77030 741613878 501 (C)(3) 138000 0 DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501 (C)(3) 201250 0 INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02215 042774441 501 (C)(3) 264500 0 BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT) BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02215 042774441 501 (C)(3) 57500 0 TRACKING INFLAMMATION AND REPAIR AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02215 042774441 501 (C)(3) 344528 0 NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVE BOSTON MA 02215 042774441 501 (C)(3) 80500 0 HOW BODY-BRAIN INFLAMMATORY SIGNALS VIA BORDER MACROPHAGES ALTER THE NEUROIMMUNE LANDSCAPE AND DRIVE ALZHEIMER'S PATHOLOGY BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 575000 0 APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 431250 0 A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 201250 0 VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 228900 0 DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS STREET BOSTON MA 02215 042312909 501 (C)(3) 201234 0 T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE BURKE NEUROLOGICAL INSTITUTE 785 MAMARONECK AVE WHITE PLAINS NY 106052523 133434924 501 (C)(3) 173007 0 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE CARNEGIE MELLON UNIVERSITY 5000 FORBES AVE PITTSBURGH PA 15213 250969449 501 (C)(3) 201250 0 INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 135598093 501 (C)(3) 201250 0 SEMAPHORIN REGULATION OF DISEASE-ASSOCIATED MICROGLIA IN ALZHEIMER'S DISEASE COLUMBIA UNIVERSITY 630 WEST 168TH STREET BOX 49 NEW YORK NY 10032 135598093 501 (C)(3) 201250 0 NONCODING TRANSLATION FEEDBACK LOOP IN ALZHEIMER'S DISEASE DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM NC 27701 562247203 501 (C)(3) 204656 0 CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE DUKE UNIVERSITY SCHOOL OF MEDICINE 324 BLACKWELL STREET SUITE 900 DURHAM NC 27701 562247203 501 (C)(3) 320033 0 UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES EMORY UNIVERSITY 1599 CLIFTON ROAD NE 4TH FLOOR 1599-001-1BA ATLANTA GA 303224250 580566256 501 (C)(3) 201250 0 MITOCHONDRIAL ALZHEIMER'S RISK FACTORS CONTROL APOE EXPRESSION AND SECRETION GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501 (C)(3) 258573 0 DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT) GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501 (C)(3) 201250 0 DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501 (C)(3) 258615 0 DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT) GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501 (C)(3) 201250 0 DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODEL HOUSTON METHODIST RESEARCH INSTITUTE (HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 201167 0 A MUTI-MODALITY STUDY ON LIPID MOLECULAR BASIS OF OBESITY AND ITS ROLES IN REGULATING ALZHEIMER'S PATHOGENESIS FOR DEVELOPING POTENTIAL TARGETED INTERVENTIONS HOUSTON METHODIST RESEARCH INSTITUTE (HOUSTON METHODIST HOSPITAL FOUNDATION PO BOX 4384 HOUSTON TX 77210 760094743 501 (C)(3) 57500 0 CANCER-DERIVED EXTRACELLULAR VESICLE MICRORNAS AS SYSTEMIC MODULATORS OF ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201235 0 RESTORING BRAIN COLLECTION IN NEW YORK CITY THROUGH THE MOUNT SINAI NEUROPATHOLOGY BRAIN BANK ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 150786 0 ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 230000 0 INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 80500 0 COMBINATORIAL ROLES OF EED AND PICALM IN MICROGLIAL CLEARANCE PATHWAYS IN ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 INVESTIGATING MEF2C TRANSCRIPTION FACTOR AS THERAPEUTIC TARGET TO REPROGRAM PATHOLOGICAL MICROGLIAL STATES IN ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 115000 0 CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE BOX 1075 NEW YORK NY 10029 136171197 501 (C)(3) 201250 0 ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501 (C)(3) 201250 0 A TEMPORALLY ALIGNED MULTIMODAL FRAMEWORK FOR INDIVIDUALIZED ALZHEIMER'S DISEASE RISK ASSESSMENT AND DEEP LEARNING-DRIVEN PROGNOSIS JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501 (C)(3) 143697 0 BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY JOHNS HOPKINS UNIVERSITY 733 N BROADWAY MRB SUITE 117 BALTIMORE MD 21205 520595110 501 (C)(3) 201250 0 FROM MOLECULAR HETEROGENEITY TO PREDICTIVE MEDICINE: TRANSFORMING NEURODEGENERATIVE DISEASE RESEARCH THROUGH SPATIAL MULTI-OMICS AND INTERPRETABLE AI MARYLAND MEDICAL LEGAL FOUNDATION 900 WEST BALTIMORE STREET BALTIMORE MD 21223 520786068 501 (C)(3) 57500 0 BRIDGE FUNDING FOR A YOUNGER DIVERSE HUMAN BRAIN BANK TO INVESTIGATE EARLY AD PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 287500 0 BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 4025 0 ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS (SUPPLEMENT) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 RIN3 AND BIN1 INTERACTION CONNECTS ENDOSOMAL PATHOLOGY WITH AMYLOID PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 PRECISION GENE THERAPY TARGETING MICROGLIA IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 ENGINEERING A HUMAN REGION-SPECIFIC SYSTEM TO PROBE APOE-LINKED CELLULAR VULNERABILITY AND RESILIENCE IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 100625 0 AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 258750 0 EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT) MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 201250 0 CENTENARIAN MICROGLIA REVEAL A NEPRILYSIN-DEPENDENT MECHANISM OF RESILIENCE IN ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 230000 0 ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 1955000 0 THE CUREALZ ALZHEIMER'S GENOME PROJECT MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 100600 0 ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS MASSACHUSETTS GENERAL HOSPITAL 125 NASHUA ST SUITE 540 BOSTON MA 02114 041564655 501 (C)(3) 100625 0 CHARACTERIZATION AND OPTIMIZATION OF CNS-PENETRANT HDAC11-SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 258750 0 ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 252076 0 MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 201250 0 IDENTIFYING SEX-AWARE X-CHROMOSOME TARGETS FOR PRECLINICAL ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 300000 0 UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 8533 0 ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (SUPPLEMENT) MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 201250 0 CIRCUIT DYNAMICS IN APOE4 MICE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 201250 0 INTERNEURON THERAPY FOR ALZHEIMER'S DISEASE MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 201250 0 DEVELOPMENT OF A FLAP-TARGETED NEUROIMMUNE PET TRACER FOR IMAGING MICROGLIA IN AD MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501 (C)(3) 200416 0 CIRCADIAN PERTURBATIONS OF THE VASCULOME AND MICROGLIOME IN ALZHEIMER'S DISEASE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501 (C)(3) 287477 0 BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501 (C)(3) 9752 0 DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE (SUPPLEMENT) MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 322241865 593337028 501 (C)(3) 201250 0 LINKING SLEEP DYSFUNCTION TO TAU-RELATED DEGENERATION ACROSS AD VARIANTS MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 322241865 593337028 501 (C)(3) 201250 0 THE MULTI-OMIC ROADMAP TO NEURONAL SENESCENCE IN ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 322241865 593337028 501 (C)(3) 230000 0 UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 322241865 593337028 501 (C)(3) 201250 0 EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS MAYO CLINIC JACKSONVILLE 4500 SAN PABLO ROAD JACKSONVILLE FL 322241865 593337028 501 (C)(3) 201250 0 ELUCIDATING THE PROTECTIVE EFFECTS OF APOE2 IN THE PRESENCE OF APOE 4 GENE ALLELE IN ANIMAL MODELS MAYO CLINIC ROCHESTER 200 FIRST ST SW ROCHESTER MN 55905 416011702 501 (C)(3) 201250 0 BRIDGING THE GAP: SEX-SPECIFIC DRIVERS OF SENESCENCE UNDERLYING NEURODEGENERATION MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE NEW YORK NY 10065 131924236 501 (C)(3) 201250 0 DEVELOPMENT AND MECHANISM OF AUTOPHAGY ACTIVATORS FOR TREATMENT OF ALZHEIMER'S DISEASE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE 900 ROCKVILLE PIKE BETHESDA MD 20892 520858115 GOVERNMENT 287673 0 BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE 900 ROCKVILLE PIKE BETHESDA MD 20892 520858115 GOVERNMENT 80500 0 DYNAMIC INVESTIGATION OF LYMPHATIC PATHWAY INTERCONNECTIONS FOR CEREBROSPINAL FLUID CLEARANCE OF THE HUMAN CENTRAL NERVOUS SYSTEM IN VIVO UNDER PHYSIOLOGICAL CONDITIONS OF THE BRAIN'S BORDERS SEATTLE NEUROSOUND SOLUTIONS 1126 38TH AVENUE EAST SEATTLE WA 98112 884199640 175000 0 CONTINUOUS MONITORING AND ENHANCEMENT OF GLYMPHATIC FLOW IN HUMAN SLEEP NEW YORK GENOME CENTER 101 AVENUE OF THE AMERICAS 7TH FLOOR NEW YORK NY 10013 800631734 501 (C)(3) 86250 0 CROSS-SPECIES ANALYSIS OF MICROGLIAL STATES IN HETEROGENEOUS ALZHEIMER'S DISEASE PROGRESSION NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 201250 0 MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE-ONSET ALZHEIMER'S DISEASE IN WOMEN NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 210962 0 MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 287500 0 NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 80500 0 ASTROCYTE NETWORK STRUCTURE AND FUNCTION IN ALZHEIMER'S DISEASE NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVE NEW YORK NY 10016 135562308 501 (C)(3) 201250 0 VIRAL INFECTIONS AND ALZHEIMER'S DISEASE RISK IN WOMEN NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE ABBOTT 1416 CHICAGO IL 60611 362167817 501 (C)(3) 201250 0 SEX-SPECIFIC MECHANISMS OF NEUROINFLAMMATION IN THE ALZHEIMER'S DISEASE HYPOTHALAMUS NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE ABBOTT 1416 CHICAGO IL 60611 362167817 501 (C)(3) 201250 0 ROLE OF TAU IN PRESYNAPTIC DYSFUNCTION DURING THE CELLULAR PHASE OF ALZHEIMER'S DISEASE NORTHWESTERN UNIVERSITY 710 N LAKE SHORE DRIVE ABBOTT 1416 CHICAGO IL 60611 362167817 501 (C)(3) 57500 0 ROLE OF ANNEXIN A6-MEDIATED MEMBRANE REPAIR IN ALZHEIMER'S PATHOLOGY PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 38944 0 PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA (SUPPLEMENT) PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 230000 0 MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 80500 0 FBAT-EQUIVALENCE TESTING IN THE PRESENCE OF MODEL UNCERTAINTY FOR THE CURE ALZHEIMERS GENOME PROJECT PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSETTS AVE 3RD FLOOR CAMBRIDGE MA 02138 042103580 501 (C)(3) 201250 0 MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 201250 0 DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 150937 0 THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 201250 0 SON-DEPENDENT NUCLEAR SPECKLE REJUVENATION: A NOVEL PROTEOSTASIS-BASED THERAPEUTIC STRATEGY FOR ALZHEIMER'S DISEASE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 287500 0 BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 80500 0 MECHANISMS REGULATING NEUROVASCULAR FUNCTION IN ALZHEIMER'S DISEASE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 287500 0 NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0934 LA JOLLA CA 920930636 952872494 501 (C)(3) 230000 0 APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME ST JUDE CHILDREN'S RESEARCH HOSPITAL 262 DANNY THOMAS PLACE MEMPHIS TN 38105 620646012 501 (C)(3) 92000 0 DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY CA 94063 941156365 501 (C)(3) 198253 0 BMP LIPID METABOLISM AS A THERAPEUTIC TARGET FOR LYSOSOMAL FUNCTION AND ALZHEIMER'S DISEASE PATHOGENESIS STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY CA 94063 941156365 501 (C)(3) 198370 0 OLIGODENDROGLIAL DYNAMICS AND MYELINATION IN ALZHEIMER'S DISEASE STANFORD UNIVERSITY 485 BROADWAY REDWOOD CITY CA 94063 941156365 501 (C)(3) 287500 0 BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE STATE OF MARYLAND -UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 526002033 501 (C)(3) 171037 0 EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS THE BROAD INSTITUTE INC 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501 (C)(3) 230000 0 INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS THE MCLEAN HOSPITAL CORPORATION 115 MILL STREET BELMONT MA 02478 042697981 501 (C)(3) 327501 0 EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 943067788 501 (C)(3) 201250 0 NEURONAL MECHANISMS DRIVING SYNAPSE LOSS IN ALZHEIMER'S DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 943067788 501 (C)(3) 201250 0 PROBING THE MOLECULAR UNDERPINNINGS OF HOW G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATES PROTECTIVE RESPONSES TO ALZHEIMER'S DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 943067788 501 (C)(3) 80500 0 DEFINE ADGRG1-MEDIATED PROTECTIVE MICROGLIAL RESPONSE TO TAU TANGLES IN ALZHEIMER'S DISEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 490 ILLINOIS STREET 4TH FLOOR SAN FRANCISCO CA 94143 943067788 501 (C)(3) 201250 0 ROLE OF PLATELET-DERIVED FACTORS IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 10010 NORTH TORREY PINES ROAD LA JOLLA CA 92037 952160097 501 (C)(3) 201250 0 THE ROLE OF ASTROCYTE-SECRETED IGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE TRUSTEES OF TUFTS COLLEGE DBA TUFTS UNIVERSITY 80 GEORGE ST MEDFORD MA 02155 042103634 501 (C)(3) 100625 0 ELUCIDATING THE INTERPLAY BETWEEN AD GENETIC VARIANTS USING HUMAN IPSC-DERIVED MICROGLIA-LIKE CELLS UNIVERSITY OF ALABAMA AT BIRMINGHAM 801 5TH AVE SOUTH ROOM 251 BIRMINGHAM AL 35233 636005396 501 (C)(3) 271375 0 EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK UNIVERSITY OF CALIFORNIA DAVIS ONE SHIELDS AVENUE DAVIS CA 95616 943067788 501 (C)(3) 201250 0 DECIPHERING PHOSPHORYLATION-DEPENDENT TAU ENVELOPE DYSFUNCTION TO PREVENT ALZHEIMER'S NEURODEGENERATION UNIVERSITY OF CALIFORNIA DAVIS ONE SHIELDS AVENUE DAVIS CA 95616 943067788 501 (C)(3) 286466 0 NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE CA 92697 952226406 501 (C)(3) 287490 0 NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE CA 92697 952226406 501 (C)(3) 230000 0 ENGINEERED CAR-MACROPHAGES TO CLEAR TAU UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE CA 92697 952226406 501 (C)(3) 402492 0 PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BOULEVARD SUITE 600 LOS ANGELES CA 90024 956006143 501 (C)(3) 191463 0 NOVEL AI DECODES AGING NEURONS UNIVERSITY OF KENTUCKY 109 KINKEAD HALL LEXINGTON KY 405060057 616033693 501 (C)(3) 78090 0 ASSESSING THE ROLE OF APOE IN GLIAL LIPID DROPLET METABOLISM AND FUNCTION UNIVERSITY OF KENTUCKY 109 KINKEAD HALL LEXINGTON KY 405060057 616033693 501 (C)(3) 200187 0 LOWERING MICROGLIAL LIPID BURDEN VIA PLIN2 MODULATION IN ALZHEIMER'S DISEASE UNIVERSITY OF MASSACHUSETTS CHAN MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 01655 043167352 501 (C)(3) 200568 0 VENTRICULAR EPENDYMAL CELLS: A NOVEL NEURAL-IMMUNE SIGNALING AXIS DURING AGING AND NEURODEGENERATION UNIVERSITY OF MIAMI PO BOX 405803 ATLANTA GA 30384 590624458 501 (C)(3) 24589 0 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 481091287 386006309 501 (C)(3) 398521 0 UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 481091287 386006309 501 (C)(3) 201251 0 MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 481091287 386006309 501 (C)(3) 402500 0 NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES UNIVERSITY OF MICHIGAN 3003 SOUTH STATE STREET ANN ARBOR MI 481091287 386006309 501 (C)(3) 103168 0 NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET 5TH FLOOR FRANKLIN BUILDING PHILADELPHIA PA 191046205 231352685 501 (C)(3) 284678 0 APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY UNIVERSITY OF PITTSBURGH 200 S CRAIG ST SUITE 230 PITTSBURGH PA 15260 250965591 501 (C)(3) 100625 0 AN ENGINEERED PLATFORM TO MODEL THE YOLK SAC-BRAIN INTERACTIONS IN ALZHEIMER'S DISEASE UNIVERSITY OF ROCHESTER 910 GENESEE STREET SUITE 200 ROCHESTER NY 146113847 160743209 501 (C)(3) 287500 0 BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? UNIVERSITY OF SOUTH FLORIDA 4202 E FOWLER AVE SVC 1039 TAMPA FL 336205800 593102112 501 (C)(3) 201250 0 BIN1 IN MICROGLIAL HETEROGENEITY ALONG AD PROGRESSION AND MICROGLIAL FUNCTION UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA STREET SUITE 102 LOS ANGELES CA 900898001 951642394 501 (C)(3) 57500 0 NEURAL STEM CELL REJUVENATION FOR SYMPTOMATIC ALZHEIMER'S DISEASE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO TX 78229 741586031 501 (C)(3) 181004 0 BRIDGING MYELIN AND VASCULAR DEMENTIA: OLIGODENDROCYTE STRESS RESPONSES IN AGEING AND CEREBROVASCULAR DISEASE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO TX 78229 741586031 501 (C)(3) 201250 0 HOW DO MICROGLIA CONTRIBUTE TO THE SPREAD OF TAU PATHOLOGY IN ALZHEIMER'S DISEASE? UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO TX 78229 741586031 501 (C)(3) 201250 0 DIGITAL NEUROPATHOLOGY INFRASTRUCTURE FOR PRECISION MEDICINE IN SOUTH TEXAS HISPANIC AD/ADRD POPULATIONS UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO 7703 FLOYD CURL DRIVE MSC 7828 SAN ANTONIO TX 78229 741586031 501 (C)(3) 201250 0 COGNITIVELY HEALTHY NONAGENARIANS IN THE CROSS COHORT COLLABORATION (CCC) UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 501 (C)(3) 230000 0 ENGINEERED CAR-MACROPHAGES TO CLEAR TAU UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 229044195 546001796 501 (C)(3) 201250 0 MICROGLIAL MITOCHONDRIAL DYSFUNCTION AND TAU TOXICITY IN ALZHEIMER'S DISEASE UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 229044195 546001796 501 (C)(3) 201250 0 IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 229044195 546001796 501 (C)(3) 258750 0 THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT) UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 229044195 546001796 501 (C)(3) 201250 0 ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD UNIVERSITY OF VIRGINIA 1001 N EMMETT ST CHARLOTTESVILLE VA 229044195 546001796 501 (C)(3) 50312 0 THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION UNIVERSITY OF WASHINGTON 4300 ROOSEVELT WAY NE BOX 354965 SEATTLE WA 98105 916001537 501 (C)(3) 200043 0 ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDO-LYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 SLEEP REINFORCES HOMEOSTATIC SET-POINTS IN NEURAL ACTIVITY AND MITIGATES NEURODEGENERATIVE DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 345000 0 APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 345000 0 BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 182921 0 MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 200530 0 MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 77709 0 SUPPRESSING NEUROINFLAMMATION WITH A TARGETED PROTEIN DEGRADATION STRATEGY IN A TAUOPATHY MOUSE MODEL WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 DECIPHERING AND RESTORING COMPUTATIONAL SET-POINTS IN ALZHEIMER'S DISEASE THROUGH SLEEP-ENHANCED NETWORK HOMEOSTASIS WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 80500 0 SLEEP AUGMENTATION REINFORCES NEURAL COMPUTATION, ENHANCES COGNITION, AND MITIGATES NEURODEGENERATIVE DISEASE SYMPTOMS WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 ANTIVIRAL CYTOKINE SIGNALING PROMOTES NEURODEGENERATION IN ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 345000 0 BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201212 0 NEUROPROTECTIVE T CELL-BASED THERAPY FOR ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 124653 0 CHARACTERIZATION OF ALZHEIMER'S DISEASE MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 199281 0 CIRCADIAN DESYNCHRONY, GLIAL DYSFUNCTION, AND ALZHEIMER DISEASE PATHOGENESIS WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 287500 0 BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 98083 0 NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATHY WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 287499 0 BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501 (C)(3) 201250 0 THE JEFFREY L. MORBY PRIZE WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 80500 0 MICROGLIAL-ASTROCYTIC MECHANISMS OF APOE3 CHRISTCHURCH-MEDIATED RESILIENCE TO TAUOPATHY WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 402500 0 SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 200532 0 HYPERTENSION, TAU AND NEURODEGENERATION WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 201250 0 A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE NEW YORK NY 100654805 136094042 501 (C)(3) 258750 0 A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT) 54 0 PART I, LINE 2: THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. X X X X X X 0 0 0 0 0 0 0 0 0 MARGARET E SMITH CEO & DIRECTOR 436310 0 65250 0 0 0 10500 0 19119 0 531179 0 0 0 KATHARINE HERMAN EVP DEVELOPMENT 372022 0 86500 0 0 0 10500 0 20535 0 489557 0 0 0 BARBARA CHAMBERS EVP MARKETING & COMM. 283531 0 19500 0 0 0 9511 0 14967 0 327509 0 0 0 LISA RAND VP MARKETING & COMM. 208091 0 9000 0 0 0 6821 0 12673 0 236585 0 0 0 DANIEL HARPER VP DEVELOPMENT 206418 0 14500 0 0 0 6731 0 7630 0 235279 0 0 0 JOSEPHINE ANTONELLIS CFO 204692 0 20500 0 0 0 6763 0 1239 0 233194 0 0 0 JOHN SLATTERY SVP, PHILANTHROPIC PARTNERSHIPS 204048 0 9500 0 0 0 6502 0 960 0 221010 0 0 0 MAHUA DASGUPTA SR. PHILANTROPIC ADVISOR 181723 0 12000 0 0 0 6237 0 20517 0 220477 0 0 0 THIDAPHORN SENGSAVANH DIRECTOR OF DEVELOPMENT OPERATIONS 163396 0 7500 0 0 0 5403 0 20279 0 196578 0 0 0 PROPER VILLAINS LLC A PRINCIPAL OF THE INDEPENDENT CONTRACTOR IS THE SPOUSE OF A KEY EMPLOYEE 130663 CREATIVE AND PRODUCTION SERVICES 0 X 92 5646939 FMV X AUCTION ITEMS 10 28302 FMV 0 1 1 PART I, LINE 32B: WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH JP MORGAN AND BANK OF NEW YORK/MELLON. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 12C EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. FORM 990, PART VI, SECTION B, LINE 15 COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE CEO AND ALL OTHER EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE. FORM 990, PART XII, LINE 2C THE ORGANIZATION DID NOT CHANGE EITHER ITS OVERSIGHT PROCESS OR SELECTION PROCESS DURING THE TAX YEAR.